wanttono
Convidecia CanSino vaccine
Convidecia CanSino vaccine
Convidecia CanSino Vaccine is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics.
Production: CanSinoBIO Biologics
Age requirements: 18 and above
Dosage: Single Dose.
European approval: March 22, 2021 (Hungary)
Storage: Safe, stable storage and transportation between 2°C and 8°C for three months, two months at 25°C, three weeks at 37°C
Effectiveness: 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination.
Pakistani authority showed an efficacy rate of 100% against severe COVID-19 disease and 74.8% at preventing all symptomatic COVID-19 disease
Advantages: Convidecia™ can be stably transported between 2°C and 8°C and stored for at least three months.
It is estimated to remain stable for over two months at 25°C and three weeks at 37°C. Making it more accessible to regions with insufficient storage facilities.
Wikipedia link: en.wikipedia.org/wiki/Convidecia
SOURCE: www.prnewswire.com/news-releases/cansinobio-announces-app...
Convidecia CanSino vaccine
Convidecia CanSino vaccine
Convidecia CanSino Vaccine is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics.
Production: CanSinoBIO Biologics
Age requirements: 18 and above
Dosage: Single Dose.
European approval: March 22, 2021 (Hungary)
Storage: Safe, stable storage and transportation between 2°C and 8°C for three months, two months at 25°C, three weeks at 37°C
Effectiveness: 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination.
Pakistani authority showed an efficacy rate of 100% against severe COVID-19 disease and 74.8% at preventing all symptomatic COVID-19 disease
Advantages: Convidecia™ can be stably transported between 2°C and 8°C and stored for at least three months.
It is estimated to remain stable for over two months at 25°C and three weeks at 37°C. Making it more accessible to regions with insufficient storage facilities.
Wikipedia link: en.wikipedia.org/wiki/Convidecia
SOURCE: www.prnewswire.com/news-releases/cansinobio-announces-app...